ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
BASEL, Switzerland, Jan. 21, 2016 -- GSK (GlaxoSmithKline) informed Basilea today that it has elected to discontinue its U.S. alitretinoin program. Global rights to Toctino (alitretinoin) were transferred to Stiefel, a GSK company, in July 2012. Basilea has the option to re-acquire the U.S. alitretinoin rights. GSK continues to commercialize Toctino in its current markets.
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Media Relations | Investor Relations |
|
Peer Nils Schröder, PhD Head Public Relations & Corporate Communications +41 61 606 1102 [email protected] |
Barbara Zink, PhD, MBA Head Corporate Development +41 61 606 1233 [email protected] |
This press release can be downloaded from www.basilea.com.
Press release (PDF) http://hugin.info/134390/R/1980584/725577.pdf
HUG#1980584
